Chronic hypoparathyroidism is a rare disorder of parathyroid hormone (PTH) deficiency, most often caused by inadvertent surgical damage during thyroid or neck surgery, in which patients can no longer regulate calcium homeostasis. Conventional therapy with active vitamin D analogs and oral calcium supplements controls overt hypocalcemia but leaves patients with chronic kidney burden, mood and cognitive complaints, and skeletal abnormalities driven by ongoing absence of PTH signaling.
The peptide-replacement field reached a turning point in 2026. Ascendis Pharma's TransCon PTH (palopegteriparatide), a long-acting prodrug of PTH(1-34), reported 5-year Phase 2 PaTH Forward data on June 11, 2026 showing 82% of patients off active vitamin D and calcium at week 266 and 95% trial completion. MBX Biosciences's canvuparatide, a once-weekly precision PTH peptide, posted a 63% responder rate at 12 weeks in the Phase 2 Avail trial (vs 31% placebo) on June 12, 2026 with a registrational Phase 3 starting Q3 2026. Entera Bio's EB612 is in development as an oral PTH(1-34) tablet. All three are competing to define what 'PTH replacement' means: physiological replication, weekly dosing convenience, or oral simplicity.
Stories here cover hypoparathyroidism trial readouts and the peptide-replacement competitive set. See [[transcon-pth]], [[canvuparatide]], and [[pth-peptide]] for adjacent threads.
Ascendis Pharma (Nasdaq: ASND) released June 11 the 5-year (Week 266) results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism, ahead of formal presentation at ENDO 2026 in Chicago. At Week 266, 82% of patients met the composite endpoint of normal serum calcium without active vitamin D and with less than 600 mg/day of calcium; nearly all participants achieved independence from conventional therapy, and 95% completed the full five years. TransCon PTH replicated endogenous PTH across kidney, intestine, CNS, and bone, with normalized urine and serum calcium, sustained bone mineral density, and quality-of-life gains. The data directly stress-tests MBX Biosciences's once-weekly canvuparatide Phase 2 readout from June 12, which posted 63% responder at 12 weeks and 57% at one year.
The Endocrine Society's annual meeting ENDO 2026 opened today at McCormick Place West in Chicago and runs through Tuesday June 16, drawing roughly 7,200 attendees and nearly 2,500 abstracts spanning diabetes, obesity, reproductive health, bone health, endocrine-disrupting chemicals, and thyroid cancer. Saturday's plenary 'Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology' features I. Sadaf Farooqi (Cambridge) on single-cell genomics and Holly A. Ingraham (UCSF) on hormones and brain-body physiology. Peptide-anchored programs concentrated in the hypoparathyroidism (Ascendis, MBX, Entera), acromegaly (Crinetics), and oral GLP-1 (Entera EB618 preclinical) tracks; oncology-peptide tracks include OAR-targeted radioligand abstracts and copper-peptide bone-resorption work.
MBX Biosciences (Nasdaq: MBX) on June 12 reported full 12-week Phase 2 Avail data and one-year open-label extension results for once-weekly canvuparatide, a precision PTH peptide for chronic hypoparathyroidism. The trial hit its primary endpoint with a 63% responder rate versus 31% on placebo at 12 weeks; the OLE delivered a 79% responder rate at six months and 57% at one year. Patients showed normalized serum calcium, reduced urine calcium excretion, restored bone metabolism, and improved eGFR; 90% of OLE patients remained on study at one year with no new safety signals. A registrational Phase 3 in chronic hypoparathyroidism starts Q3 2026.